Our study, which examines the efficacy of ketamine in preventing relapse to opioids during protracted opioid abstinence and aims to identify the neural substrates for its efficacy, has commenced (EudraCT number, 2022-001997-70).

We express our gratitude to the Research and Innovation Foundation of Cyprus for funding our study (EXCELLENCE/0421/0543).

We employ blood-based biomarkers and EEG measurements to elucidate the mechanisms of action of ketamine as a novel treatment for opioid addiction.